All In Biotech

Drug Trial Radar · NCT04641312

A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3457263 in Healthy Participants and in Patients With Type 2 Diabetes

Last checked: Nov 19, 2026Latest source record: Jan 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

67

Actual

Start

Nov 25, 2020

Primary completion

Dec 21, 2021

Study completion Dec 21, 2021

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Nov 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 20 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study is to investigate the safety and tolerability of the study drug LY3457263 in healthy participants and participants with type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study has two parts (part A and B). Each part will last up to 10 weeks and may include up to either 13 (part A) or 19 (part B) visits.

Conditions

  • Healthy
  • Type 2 Diabetes

Interventions

  • LY3457263Drug

    Administered SC

  • DulaglutideDrug

    Administered SC

  • PlaceboDrug

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationTime frame: Baseline through Day 42

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Profil Mainz

    Mainz, Germany

  • Profil Institut für Stoffwechselforschung

    Neuss, North Rhine-Westphalia, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.